Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › autoimmune disorders

Autoimmune disorders

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for autoimmune disorders

25 trials tracked for autoimmune disorders: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 587 citations.

25Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 7 Phase 2 3 Phase 1 9 Other / NA 6
  1. Phase 3 Scleroderma: Cyclophosphamide or Transplantation Completed · 587 cited
  2. Phase 3 Intravenous Immunoglobulin for PANDAS Completed · 124 cited
  3. Phase 3 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Completed · 73 cited
  4. Phase 3 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Completed · 42 cited
  5. Phase 3 Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate Completed
  6. Phase 3 Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Completed
Show 19 more trials
  1. Phase 3 Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA) Completed
  2. Phase 2 Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Completed
  3. Phase 2 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed
  4. Phase 2 Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes Completed
  5. Phase 1 A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects Completed
  6. Phase 1 A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants Completed
  7. Phase 1 A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects Completed
  8. Phase 1 A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 Completed
  9. Phase 1 A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses Completed
  10. Phase 1 Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 Completed
  11. Phase 1 Phase I Study of GSK2982772 in Japanese Healthy Male Participants Completed
  12. Phase 1 A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses Completed
  13. Phase 1 Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers Completed
  14. N/A A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts Completed
  15. N/A Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes Completed
  16. N/A Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies Completed
  17. N/A Epidural Stimulation in Multiple Sclerosis Completed
  18. N/A Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain Completed
  19. N/A Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review explores mitochondrial transfer mechanisms in immune microenvironment remodeling across diseases
Allergy & Immunology Sys. Review
Review explores mitochondrial transfer mechanisms in immune microenvironment remodeling across diseases Review explores how cells share mitochondria to influence immune responses in disease
A systematic review summarizes emerging evidence on intercellular mitochondrial transfer mechanisms in inflammation, cancer, and autoimmune …
Cells swap energy factories to reshape immune responses in cancer, inflammation, and autoimmune diseases, offering new ways to target these …
Frontiers Apr 2, 2026

Questions about autoimmune disorders

What new treatments for autoimmune diseases are emerging from cancer research?

Cancer research is producing new treatments for autoimmune diseases by adapting cell therapies like CAR-T cells and targeting shared inflammatory pathways such as IRAK4 and mitochondrial transfer.

Full answer →
Can mitochondrial transfer between cells help reduce inflammation in autoimmune diseases?

Mitochondrial transfer between cells can reduce inflammation in autoimmune diseases by reprogramming immune cells to stop overactive responses and calm the immune system.

Full answer →
How might hematopoietic stem cell therapies impact patients with autoimmune diseases?

Hematopoietic stem cell (HSC) therapies can reset the immune system to stop autoimmune attacks, though they carry risks like infection and require careful nutrition and monitoring.

Full answer →
What conditions besides cancer are linked to Siglec signaling pathways?

Siglec signaling pathways are linked to autoimmune and inflammatory disorders, neurodegeneration, and infections in addition to cancer.

Full answer →
Are there therapeutic opportunities for autoimmune disorders in cancer research?

Research shows that targeting shared molecular pathways like Siglec signaling, mitochondrial cell death, and immune metabolism offers new ways to treat both autoimmune disorders and cancer.

Full answer →
How does sialidase biology relate to treating autoimmune disorders?

Sialidase biology relates to autoimmune disorders by regulating immune signals through sialic acid, a process that can be targeted to restore balance in the immune system.

Full answer →
See all 6 questions about autoimmune disorders →